Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Cash from Financing Activities came in at $30.1 million in Q1 2026, down 73.9% year-on-year from $115.5 million in Q1 2025, and down 71.39% quarter-over-quarter from $105.3 million in Q4 2025.

Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends

Oculis Holding AG's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 73.9% year-over-year to $30.1 million in Q1 2026; TTM through Mar 2026 was $134.1 million, a 23.41% decrease from a year earlier, with the FY2025 full-year figure at $225.4 million, up 267.45% from the prior year.
  • Cash from Financing Activities slipped to $30.1 million in Q1 2026 per OCS's latest filing, from $105.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $115.5 million in Q1 2025 and bottomed at -$2.1 million in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $30.2 million.
  • Across the five-year window, Cash from Financing Activities sank 264.05% in 2024 and jumped 58848.04% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$288570.1 in 2022, then surged by 264.08% to $473488.9 in 2023, then surged by 549.73% to $3.1 million in 2024, then surged by 3324.12% to $105.3 million in 2025, then plunged by 71.39% to $30.1 million in 2026.
  • Per Business Quant, the three latest OCS Cash from Financing Activities figures stand at $30.1 million (Q1 2026), $105.3 million (Q4 2025), and -$2.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 30.14 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 53,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 68.63 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 238.74 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 15.71 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 30.14 Mn
Mar 31, 2026 30.14 Mn
Dec 31, 2025 105.34 Mn
Dec 31, 2025 105.34 Mn
Sep 30, 2025 -2.14 Mn
Sep 30, 2025 -2.14 Mn
Jun 30, 2025 730,773.59
Jun 30, 2025 730,773.59
Mar 31, 2025 115.49 Mn
Mar 31, 2025 115.49 Mn
Dec 31, 2024 3.08 Mn
Dec 31, 2024 3.08 Mn
Sep 30, 2024 -850,650.74
Sep 30, 2024 -850,650.74
Jun 30, 2024 57.33 Mn
Jun 30, 2024 57.33 Mn
Mar 31, 2024 195,911.68
Mar 31, 2024 195,911.68
Dec 31, 2023 473,488.88
Dec 31, 2023 473,488.88